Theranostics · 2026
A peptide-based PROTAC targeting FOXM1 suppresses fibrosis-associated hepatocarcinogenesis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Dingyu, Duan Lei, Tan Di, Hua Xinyi, Liang Anping, Huai Ruiping, Qi Shanshan, Shang Zhixian, Jia Shijie, Qi Hui, Liu Xinrong, Zhao Jieling, Jiang Yuhong, Tan Rui, Mao Canquan
Аннотация
BACKGROUND: Liver fibrosis is not only a major cause of cirrhosis but also an important risk factor for hepatocellular carcinoma (HCC). Currently, few drugs can effectively reverse established liver fibrosis. FOXM1, a transcription factor aberrantly activated in chronic liver disease, has been implicated in fibrosis-associated hepatocarcinogenesis. Nevertheless, effective pharmacological strategies for targeting FOXM1 are still lacking.
METHODS: We developed peptide-based proteolysis-targeting chimeras (PROTACs) by conjugating the FOXM1-binding peptide P49 with different E3 ligase ligands. Among them, P49-PROTACVHL showed the most potent FOXM1-degrading activity in HCC cells and was selected for further investigation. Its therapeutic efficacy was then evaluated in CCl4-induced liver fibrosis and DEN/CCl4-induced hepatocarcinogenesis mouse models. Transcriptome analysis was performed to elucidate the molecular mechanisms by which FOXM1 promotes fibrosis and tumor progression.
RESULTS: Mechanistically, P49-PROTACVHL recruited FOXM1 to the VHL E3 ligase, leading to its polyubiquitination and subsequent proteasomal degradation. In HCC cells, FOXM1 degradation inhibited proliferation, induced cell cycle arrest, and triggered apoptosis. In the CCl4 model, P49-PROTACVHL attenuated liver fibrosis, as evidenced by reduced collagen deposition, decreased α-SMA expression, and improved liver function. Mechanistic analyses, including dual-luciferase reporter assays, revealed that ADAMTS12 is a candidate transcriptional target of FOXM1. In the DEN/CCl4 model, P49-PROTACVHL modulated the FOXM1-ADAMTS12 axis, thereby mitigating fibrosis and suppressing hepatocarcinogenesis.
CONCLUSIONS: The FOXM1-ADAMTS12 axis may represent an important molecular link between liver fibrosis and hepatocarcinogenesis. Targeting FOXM1 with peptide-based PROTACs may provide a promising therapeutic strategy to attenuate liver fibrosis and suppress HCC development.
METHODS: We developed peptide-based proteolysis-targeting chimeras (PROTACs) by conjugating the FOXM1-binding peptide P49 with different E3 ligase ligands. Among them, P49-PROTACVHL showed the most potent FOXM1-degrading activity in HCC cells and was selected for further investigation. Its therapeutic efficacy was then evaluated in CCl4-induced liver fibrosis and DEN/CCl4-induced hepatocarcinogenesis mouse models. Transcriptome analysis was performed to elucidate the molecular mechanisms by which FOXM1 promotes fibrosis and tumor progression.
RESULTS: Mechanistically, P49-PROTACVHL recruited FOXM1 to the VHL E3 ligase, leading to its polyubiquitination and subsequent proteasomal degradation. In HCC cells, FOXM1 degradation inhibited proliferation, induced cell cycle arrest, and triggered apoptosis. In the CCl4 model, P49-PROTACVHL attenuated liver fibrosis, as evidenced by reduced collagen deposition, decreased α-SMA expression, and improved liver function. Mechanistic analyses, including dual-luciferase reporter assays, revealed that ADAMTS12 is a candidate transcriptional target of FOXM1. In the DEN/CCl4 model, P49-PROTACVHL modulated the FOXM1-ADAMTS12 axis, thereby mitigating fibrosis and suppressing hepatocarcinogenesis.
CONCLUSIONS: The FOXM1-ADAMTS12 axis may represent an important molecular link between liver fibrosis and hepatocarcinogenesis. Targeting FOXM1 with peptide-based PROTACs may provide a promising therapeutic strategy to attenuate liver fibrosis and suppress HCC development.